Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing One hundred thirty-six patients had baseline CNS ...

Adjuvant alectinib improves disease-free survival compared with platinum-based chemotherapy among patients with resected ALK-positive non-small cell lung cancer (NSCLC), according to a study published ...

The data come from two studies — ALUR (NCT02604342) and ALEX (NCT02075840) — that were reported here on Monday at the European Society for Medical Oncology (ESMO) 2017 Congress. Both are phase 3 ...

A late-breaking abstract at the 2017 American Society of Clinical Oncology Annual Meeting showed that alectinib demonstrates efficacy and favorable tolerability compared with crizotinib in the primary ...

Here Dolph Lundgren discussed his kidney cancer diagnosis (specifically renal cell carcinoma) in 2015, its recurrence in 2020 and how a key ALK mutation was first missed.

Alectinib should not be used in patients who are allergic to the drug, patients with the history of liver or lung disease, exposure to excessive sunlight, during pregnancy or breast feeding. Alectinib ...

The US Food and Drug Administration (FDA) has approved alectinib (Alecensa, Genentech) in the adjuvant setting following tumor resection in patients with anaplastic lymphoma kinase (ALK)–positive ...

A subanalysis of the phase III ALEX study has shown that alectinib 600 mg twice daily is more effective than standard of care crizotinib in Asian patients with anaplastic lymphoma kinase (ALK) ...

The lung cancer drug alectinib (Alecensa) is more potent when taken with a fuller breakfast, or lunch, than when taken with a low-fat breakfast, researchers report. The Dutch team evaluated 20 ...

The appraisal committee considered evidence submitted by Roche and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence. The ...

Within 3 months of being granted priority review, alectinib (Alecensa) has been approved for patients with advanced ALK-positive non-small cell lung cancer (NSCLC) whose disease has progressed or who ...

The appraisal committee considered evidence submitted by Roche and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence. The ...